Inclusion Criteria:  Patients with biopsy proven localized prostate cancer in whom prostate radiation and ADT is appropriate therapy (such as Intermediate Risk localized prostate cancer) Patients must have at least 1 MRI detected; biopsy proven prostate cancer.  Patients diagnosed as one of the following:  National Comprehensive Cancer Network (NCCN) intermediate risk prostate cancer, OR NCCN high risk prostate cancer due to Gleason Grade 4 or 5 AND refuses to receive systemic ADT, OR NCCN high risk prostate cancer due to Prostate Specific Antigen (PSA) > 20 AND refuses to receive systemic ADT. Age >18 years.  Exclusion Criteria:  NCCN high risk patients eligible for treatment with systemic ADT who do not refuse systemic ADT. Patients receiving prior radiotherapy or surgery for prostate cancer. Patients receiving prior or ongoing ADT. Study participant unwilling or unable to undergo MRI, including patients with contra-indications to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips, etc. Use of 5 alpha reductase inhibitors (e.g. Finasteride or Dutasteride) within 3 months of screening or total use within the last two years prior to screening of > 3 months. Prostate volume more than 80 cc at prior MRI imaging. International Prostate Symptom Score ≥ 20.